| Document |
Document Title |
|
WO/2019/154795A1 |
The present invention relates to 3-(benzylamino)-4-(cyclohexylamino)-N-(2-(piperazin-1-yl)eth
yl)benzenesulfonamide derivatives and related ferrostatin-1 (Fer-1) analogues as cell death inhibitors by inhibition of ferroptosis and/or oxyt...
|
|
WO/2019/152536A1 |
The present disclosure relates to compounds that are capable of modulating the WNT/Beta-Catenin pathway. The disclosure further relates to methods of treating colorectal cancer and other WNT/Beta-Catenin mediated cancers.
|
|
WO/2019/150895A1 |
Provided is an electrolyte capable of improving the high-temperature storage characteristics and cycle characteristics of an electrochemical device. The electrolyte includes at least one type of compound indicated by general formula (1â€...
|
|
WO/2019/149091A1 |
The present invention relates to the field of compounds, and in particular to a probucol derivative, a preparation method therefor and use thereof, the probucol derivative having a structure represented by general formula I. The probucol...
|
|
WO/2019/144805A1 |
Provided are a substituted phenylethylamine compound as a μ opioid receptor agonist, a pharmaceutical composition comprising same, a preparation method therefor and the use of same for preventing and/or treating diseases associated with...
|
|
WO/2019/143782A1 |
A plasticized PVC composition free of phthalate is disclosed. The composition comprises a tertiary diamide plasticizer prepared from biorenewable feedstock such as fatty acid selected from tall oil fatty acids, tall oil fatty acid monome...
|
|
WO/2019/141740A1 |
The present invention related to compounds of Formula (I): or an agronomically acceptable salt thereof, wherein Q, X, Z, R2 and R3 are as described herein. The inventions further relates to compositions comprising said compounds, to meth...
|
|
WO/2019/142192A1 |
Novel compounds capable of inhibiting methionine metabolic pathway are provided. These compounds are used in inhibiting cystathionin γ-synthase (CGS) in general, and in plants, fungi and bacteria, in particular. These compounds of the i...
|
|
WO/2019/139899A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/139902A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/139900A1 |
Compounds of Formula (I) are provided herein. Such compounds, as well as pharmaceutically acceptable salts and compositions thereof, are useful for treating diseases or conditions, including conditions characterized by excessive cellular...
|
|
WO/2019/136112A1 |
The present invention provides a compound of formula (II): an inhibitor of indoleamine 2,3-dioxygenase (IDO), which may be used as medicaments for the treatment of proliferative disorders, such as cancer, viral infections and/or autoimmu...
|
|
WO/2019/125655A1 |
The disclosure is related to EMM-31 materials, processes, and uses of the same as reagents used in the preparation of the EMM-31 materials, process and intermediates for preparing these reagents.
|
|
WO/2019/115498A1 |
The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use ...
|
|
WO/2019/116260A1 |
A perfluorinated 1-alkoxypropene represented by general Formula (I), compositions that include such compounds, and methods and systems that include such compositions are provided, wherein Formula (I) is represented by: RfO-CF=CFCF3 where...
|
|
WO/2019/111225A1 |
Compounds and compositions are provided having the structure of Formula (I) or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein T, T', U, U', V, W, R1, R2, R3', n, o, o', o'', and o''' are as defined herein....
|
|
WO/2019/109934A1 |
The present invention provides a salt of a phenylpropionamide derivative and a preparation method therefor. The present invention specifically provides an acetate, hydrochloride, phosphate, citrate, benzoate, or fumarate of 4-amino-1-((2...
|
|
WO/2019/106490A1 |
The present invention is directed towards a process for the preparation of Cariprazine (Ia) or a pharmaceutically acceptable salt thereof, wherein, N,N- dimethyl-1H-imidazole-1-carboxamide alkyl halide (VII) is reacted with trans-4- (2-(...
|
|
WO/2019/104030A1 |
Provided are compounds of Formula I, or pharmaceutically acceptable salts thereof, and methods for their use as Nrf2 activators and for their production.
|
|
WO/2019/103990A1 |
An electrically debondable adhesive composition is described. The adhesive is comprised of a basic ionic liquid and an optionally crosslinked polymer, wherein the basic ionic liquid is comprised of a cyclic amino-ammonium cation and a bi...
|
|
WO/2019/101142A1 |
The present invention provides a dibutylfluorene derivative, an application thereof as a photoinitiator, and a preparation method of the same. The present invention also provides a photocurable composition comprising the compound and a m...
|
|
WO/2019/099873A1 |
The discovery of mutant or fusion kinases that drive oncogenesis, and the subsequent approval of specific inhibitors for these enzymes, has been instrumental in the management of some cancers. However, acquired resistance remains a signi...
|
|
WO/2019/094732A1 |
The present disclosure provides compounds of Formula (I), and pharmaceutically acceptable salts thereof. The compounds described herein are useful in treating diseases associated with the binding of CREB to CREB-binding protein (CBP) and...
|
|
WO/2019/087626A1 |
Provided are: a compound which can be used suitably as a photodegradable base in a resist composition that has good sensitivity to an active energy, has excellent resolution in lithography and enables the reduction in line width roughnes...
|
|
WO/2019/090088A1 |
Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
|
|
WO/2019/082900A1 |
The purpose of the present invention is to provide a rubber composition having excellent processability, a heteroring-modified glycerin fatty acid ester, and a production method for the heteroring-modified glycerin fatty acid ester. The ...
|
|
WO/2019/077106A1 |
The present invention relates to new compounds of general formula (I) showing great affinity and activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channel...
|
|
WO/2019/075976A1 |
Disclosed is a method for preparing roxatidineacetatehydrochloride and an intermediate thereof, comprising the following steps: dissolving m-hydroxybenzaldehyde in a solvent, dropping piperidine into the solution, adding sodium borohydri...
|
|
WO/2019/070709A1 |
The present invention provides compounds, compositions and methods for treating and/or preventing a flavivirus infection by administering such compounds and compositions.
|
|
WO/2019/063696A1 |
The invention relates to primary para-phenylenediamine compounds substituted with an aliphatic chain comprising a cationic heterocyclic group according to formula (I), as well as the organic or mineral acid or base addition salts thereof...
|
|
WO/2019/063015A1 |
Provided is a sulfonyl-substituted bicyclic compound (A) which acts as a RORγ inhibitor, which compound has a good RORγ inhibitory activity. It is hoped that same is used for treating diseases, which are mediated by a RORγ receptor, i...
|
|
WO/2019/056211A1 |
Disclosed is N-formyl vortioxetine, and also disclosed is a method for preparing the N-formyl vortioxetine and a stable solid preparation of vortioxetine.
|
|
WO/2019/060809A1 |
Disclosed are piperazine derivative compounds, particularly piperazine derivative compounds having a structure of Formula (I) and methods for preparing these compounds. Also disclosed are use of a therapeutically effective amount of the ...
|
|
WO/2019/056251A1 |
The present invention relates to a group of isotope labeling reagents for amino/phenolic hydroxyl labeling, and a synthesis method therefor. In a synthesis process, a reagent (such as a homologue of 6-aminocaproic acid) carrying both ami...
|
|
WO/2019/046931A1 |
Compounds of general formula IA, IB and IC outlined below, including pharmaceutically acceptable salts, solvates and hydrates thereof. Such compounds and pharmaceutical compositions comprising them may be used in medical conditions invol...
|
|
WO/2019/046330A1 |
Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
|
|
WO/2019/045035A1 |
The present invention relates to biaryloxy derivatives which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of disorders and diseases in which voltage ...
|
|
WO/2019/043372A1 |
There are described compounds of formula (I) in which X, R1, R2 and n are each as herein defined; and their use as a medicament in the treatment of conditions involving abnormal activation and/or malfunction of the hedgehog pathway, such...
|
|
WO/2019/046318A1 |
Provided herein are compounds and compositions useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.
|
|
WO/2019/042301A1 |
The present invention provides a new class of (E)-α,β-unsaturated amide compounds represented by formula I, and also relates to methods for preparing such compounds and the pharmaceutical uses thereof. The compounds have the effect of ...
|
|
WO/2019/029211A1 |
Disclosed by the present invention are an SIRT6 small-molecule allosteric activator and the application thereof, and provided is an SIRT6 small-molecule allosteric activator that contains a derivative as shown in formula (1) or a pharmac...
|
|
WO/2019/030197A1 |
The present invention relates to a process to prepare propylene amines of the formula NH2-(A-NH-)pR, wherein R is a hydrogen atom or an alkyl group, p is at least 1 when R is an alkyl group, and at least 2 when R is a hydrogen atom, or d...
|
|
WO/2019/028473A1 |
Disclosed are methods for performing dynamic nuclear polarization using the polarizing agents described herein. In general, the methods involve (a) providing a frozen sample in a magnetic field, wherein the frozen sample includes a polar...
|
|
WO/2019/019851A1 |
Disclosed are a sodium ion channel inhibitor and a pharmaceutically acceptable salt and a polymorph thereof. The sodium ion channel inhibitor is a compound having the structure as shown in formula (X). Disclosed are a method for preparin...
|
|
WO/2019/019049A1 |
The present invention provides an anti-Candida albicans piperazine derivative, a preparation method therefor and application thereof. The structural formula of the piperazine derivative is as represented by formula I, and the derivative ...
|
|
WO/2019/016595A1 |
The present invention relates to methods of treating an animal having a non-cancerous medical condition that is ameliorated by treatment with a trypsin inhibitor, the method comprising obtaining a biological sample from the animal; testi...
|
|
WO/2019/015794A1 |
The present invention relates to a chemical compound according to general formula (1).
|
|
WO/2019/016828A1 |
The present invention relates to novel processes for the preparation of trans- N-{4-[2- [4-(2,3-dichloro phenyl) piperazine-1-yl] ethyl] cyclohexyl} -N',N'-dimethylurea hydrochloride represented by the following structural formula-1a and...
|
|
WO/2019/011709A1 |
The invention pertains to a process for manufacturing a mixture of straight-chain higher ethyleneamines and non-straight-chain higher ethyleneamines selected from branched higher ethyleneamines and cyclic higher ethyleneamines, or the ur...
|
|
WO/2019/011710A1 |
The present invention relates to a process to prepare ethyleneamines of the formula NH2-(C2H4-NH-)PI-I wherein p is at least 3, or derivatives thereof wherein one or more units -NH-C2H4-NH- may be present as a cyclic ethylene urea unit o...
|
